Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches.
Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah MM, Haque S, Islam A, Hassan MM. · 2022
Read Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches. by Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah MM, Haque S, Islam A, Hassan MM. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9262248.txt.
Description
Emran and co-authors review multidrug resistance in cancer, its molecular mechanisms, and ways around it. Resistance is a major obstacle to effective cancer treatment. It can be present from the start or acquired during therapy. Chemotherapy fails in most resistant cases.
Drivers include altered genes and epigenetics, stronger drug efflux pumps, and blocked cell death. Low oxygen and autophagy inside tumors also foster resistance. The review explains resistance genes and the controls that switch them on. It then covers lab approaches to inhibit, bypass, or reverse resistance. Options range from immune prevention to microparticles and nanomedicine. The authors argue that grasping the mechanisms is the first step to better strategies.
Catalog record
| CREATOR | Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah MM, Haque S, Islam A, Hassan MM. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 214 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |